CN105998726A - Natto protein powder - Google Patents

Natto protein powder Download PDF

Info

Publication number
CN105998726A
CN105998726A CN201610342975.1A CN201610342975A CN105998726A CN 105998726 A CN105998726 A CN 105998726A CN 201610342975 A CN201610342975 A CN 201610342975A CN 105998726 A CN105998726 A CN 105998726A
Authority
CN
China
Prior art keywords
powder
parts
natto
egg
egg albumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610342975.1A
Other languages
Chinese (zh)
Inventor
王思烨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610342975.1A priority Critical patent/CN105998726A/en
Publication of CN105998726A publication Critical patent/CN105998726A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to natto protein powder, which is characterized in that the natto protein powder is prepared from the following components in parts by weight: 45 to 55 parts of natto powder, 25 to 30 parts of milk powder, 25 to 30 parts of inulin, 10 to 15 parts of puerarin powder, 5 to 10 parts of walnut powder, 5 to 10 parts of peanut powder, 2 to 8 parts of dendrobium powder, 3 to 8 parts of lettuce powder, 6 to 9 parts of lentinula edodes powder, 10 to 20 parts of garlic powder and 10 to 15 parts of egg powder. The natto protein powder can be used for dissolving thrombus and preventing formation of the thrombus.

Description

A kind of natto egg albumen powder
Technical field
The present invention relates to a kind of for thrombus, prevent thrombotic natto product, particularly relate to a kind of natto egg albumen powder.
Background technology
At present, China's cardiovascular and cerebrovascular vessel thrombotic disease is that harm middle-aged and elderly people health is the most serious and one of modal disease.According to statistics, entirely There is thrombotic disease patient about 15,000,000 people in the world, dies from cardiovascular and cerebrovascular vessel thrombotic disease about 12,000,000 people the most every year.In China, brain After wind patient discharge, the relapse rate of First Year is 30%, and the relapse rate of the 5th year is up to 59%.Owing to China is populous, pace of population aging adds Hurry up, so effectively preventing cardiovascular and cerebrovascular vessel thrombotic disease is significant.
Although existing treatment thrombosis medicine obtains significant effect, but having some limitations property, such as anticoagulant and antiplatelet drug have one Fixed side effect, and cannot thrombus main matter insoluble fibrin.
Summary of the invention
There is provided a kind of effectively prevention cardiovascular and cerebrovascular disease to occur in place of the invention aims to overcome the deficiencies in the prior art, build up resistance, Improve constipation, the natto egg albumen powder of protein of suffering from diarrhoea, supplement.
For achieving the above object, the technical scheme that the present invention takes is: a kind of natto egg albumen powder, it is characterised in that: comprise the component of following weight portion: Natto powder 45-55 part, milk powder 25-30 part, inulin 25-30 part, powder of Radix Puerariae 10-15 part, walnut powder 5-10 part, peanut powder 5-10 part, stone Dry measure used in former times powder 2-8 part, lettuce powder 3-8 part, mushroom powder 6-9 part, Bulbus Allii powder 10-20 part, egg powder 10-15 part.
Preferably: comprise the component of following weight portion: natto powder 45 parts, milk powder 25 parts, inulin 30 parts, powder of Radix Puerariae 10 parts, walnut powder 10 parts, peanut powder 5 parts, dendrobe powder 8 parts, lettuce powder 8 parts, mushroom powder 6 parts, Bulbus Allii powder 10 parts, egg powder 15 parts.
Preferably: comprise the component of following weight portion: natto powder 55 parts, milk powder 30 parts, inulin 25 parts, powder of Radix Puerariae 15 parts, walnut powder 5 parts, peanut powder 10 parts, dendrobe powder 2 parts, lettuce powder 3 parts, mushroom powder 9 parts, Bulbus Allii powder 20 parts, egg powder 10 parts.
Preferably: also comprise the adjuvant of 20-25 weight portion.
Preferably: described adjuvant includes at least in soybean lecithin, hydroxyl isomaltulose, starch, mannitol, lactose, magnesium stearate Kind.
Preferably: described natto powder uses following methods to be prepared from:
(1) actication of culture: activation medium is containing yeast extract, peptone, dipotassium hydrogen phosphate, sodium chloride, agar and distilled water, activation medium PH be 7.0～7.5, by culture medium at 119～121 DEG C after sterilizing 30min, inoculate Bafillus natt, and at temperature is 36～38 DEG C Bafillus natt is activated 24h；
(2) strain expanded culture: the culture medium that strain expands contains peptone, glucose, dipotassium hydrogen phosphate, magnesium sulfate, calcium chloride and distillation Water, the pH of culture medium is 7.0～7.5, by culture medium sterilizing 30min at 119～121 DEG C, then by the Bafillus natt after activation in temperature Degree is amplification culture 24h at 36～38 DEG C；
(3) fermentation: Drinking Water is heated up to 50～60 DEG C, 10～15% according to the water yield add soybean protein powder, are sufficiently stirred for being formed greatly Soybean protein powder suspension, then adds dipotassium hydrogen phosphate in soybean protein powder suspension, and regulation pH is 7.0～7.5, goes out at 119～121 DEG C Cool down after bacterium 30min, add the Bafillus natt after step (2) amplification culture, at 36～38 DEG C of bottom fermentation 48h；
(4) fermentation liquid after step (3) being fermented inactivates 35min at 80～85 DEG C, and being then dried under vacuum to solid content at 60～70 DEG C is After 30%, lyophilization, obtain natto powder.
Embodiment 1
A kind of natto egg albumen powder, comprises the component of following weight portion: natto powder 45 parts, milk powder 25 parts, inulin 30 parts, powder of Radix Puerariae 10 parts, Walnut powder 10 parts, peanut powder 5 parts, dendrobe powder 8 parts, lettuce powder 8 parts, mushroom powder 6 parts, Bulbus Allii powder 10 parts, egg powder 15 parts.This reality Execute selenium-rich natto product described in example and can be fabricated to chewable tablet, capsule, 400mg/ sheet, eat 2～3 every day；Or it is fabricated to powder solid beverage, Every daily warm water Instant Drinks 1～2g.
Embodiment 2
A kind of natto egg albumen powder, comprises the component of following weight portion: natto powder 55 parts, milk powder 30 parts, inulin 25 parts, powder of Radix Puerariae 15 parts, Walnut powder 5 parts, peanut powder 10 parts, dendrobe powder 2 parts, lettuce powder 3 parts, mushroom powder 9 parts, Bulbus Allii powder 20 parts, egg powder 10 parts.This reality Execute selenium-rich natto product described in example and can be fabricated to chewable tablet, capsule, 400mg/ sheet, eat 2～3 every day；Or it is fabricated to powder solid beverage, Every daily warm water Instant Drinks 1～2g.
Embodiment 3
Lee, man, 60 years old, takes natto egg albumen powder of the present invention according to the method described in embodiment 1-2 and dosage, takes three months, use colour Doppler ultrasonic diagnosis apparatus detects the carotid artery of this patient, predominantly detects the plaque within blood vessels of patient, tunica intima thickness and blood flow state.This patient Before the natto egg albumen powder taking the present invention, blood vessel speckle is obvious, and Patch size is 0.75cm × 0.22cm；Take natto egg albumen powder of the present invention After three months, this patient vessel's inwall speckle is obviously reduced, and speckle is reduced to 0.25cm × 0.10cm.This patient is taking natto egg albumen powder of the present invention Before, its blood vessel thickness is thicker, takes natto egg albumen powder of the present invention after three months, and the blood vessel thickness of this patient is obviously reduced, blood vessel wall thickness Degree recovers normal.Before this patient takes the natto egg albumen powder of the present invention, there is the situation of cutout and eddy current in its blood flow state, and takes natto of the present invention After egg albumen powder three months, blood flow rate recovers normal.This patient took the natto egg albumen powder of the present invention after three months, original cardiovascular and cerebrovascular vessel exception shape State considerably reduces, and patient feels that health is good, and especially numbness of hands and feet, asthma uncomfortable in chest, brain activity is not enough etc., and cardiovascular and cerebrovascular vessel abnormality has disappeared Lose.
King so-and-so, man, 70 years old, constipation 10 years, within nearly 1 year, occur that paroxysmal is dizzy, without tinnitus, blood pressure is on the low side at an early age, over one year blood pressure rising, Starting to take depressor, summer, blood pressure was on the low side, and drug withdrawal, it is the highest that weather turns cool rear blood pressure, continues to take depressor.Diarrhea with loose stool at an early age, closely Constipation in 10 years, stool does not does, solutions smooth, often without defecation consciousness, usually or take relieving constipation Chinese patent medicine, or with help defecations such as glycerin.Take this Invention natto egg albumen powder is after three months, and this tients with constipation's situation disappears, and blood pressure recovers normal level.
Lin, female, 54 years old, blowing was suffered from cold and is the most easily generated heat, coughs the most whenever, and more very, and Drug therapy result is not good enough for winter-spring season.Take this The tolerance of wind and cold, after three months, has been strengthened by invention natto egg albumen powder.After taking six months, catch a cold the most easily.

Claims (6)

1. a natto egg albumen powder, it is characterised in that: comprise the component of following weight portion: natto powder 45-55 part, milk powder 25-30 part, inulin 25-30 part, powder of Radix Puerariae 10-15 part, walnut powder 5-10 part, peanut powder 5-10 part, dendrobe powder 2-8 part, lettuce powder 3-8 part, mushroom powder 6-9 Part, Bulbus Allii powder 10-20 part, egg powder 10-15 part.
2. natto egg albumen powder as claimed in claim 1 a kind of, it is characterised in that: comprise the component of following weight portion: natto powder 45 parts, milk powder 25 parts, inulin 30 parts, powder of Radix Puerariae 10 parts, walnut powder 10 parts, peanut powder 5 parts, dendrobe powder 8 parts, lettuce powder 8 parts, mushroom powder 6 parts, Bulbus Allii powder 10 parts, egg powder 15 parts.
3. natto egg albumen powder as claimed in claim 1 a kind of, it is characterised in that: comprise the component of following weight portion: natto powder 55 parts, milk powder 30 parts, inulin 25 parts, powder of Radix Puerariae 15 parts, walnut powder 5 parts, peanut powder 10 parts, dendrobe powder 2 parts, lettuce powder 3 parts, mushroom powder 9 parts, Bulbus Allii powder 20 parts, egg powder 10 parts.
4. a kind of natto egg albumen powder as claimed in claim 1, it is characterised in that: also comprise the adjuvant of 20-25 weight portion.
5. a kind of natto egg albumen powder as claimed in claim 4, it is characterised in that: described adjuvant includes soybean lecithin, hydroxyl isomaltulose, shallow lake At least one in powder, mannitol, lactose, magnesium stearate.
6. a kind of natto egg albumen powder as claimed in claim 1, it is characterised in that: described natto powder uses following methods to be prepared from:
(1) actication of culture: activation medium is containing yeast extract, peptone, dipotassium hydrogen phosphate, sodium chloride, agar and distilled water, activation medium PH be 7.0～7.5, by culture medium at 119～121 DEG C after sterilizing 30min, inoculate Bafillus natt, and at temperature is 36～38 DEG C Bafillus natt is activated 24h；
(2) strain expanded culture: the culture medium that strain expands contains peptone, glucose, dipotassium hydrogen phosphate, magnesium sulfate, calcium chloride and distillation Water, the pH of culture medium is 7.0～7.5, by culture medium sterilizing 30min at 119～121 DEG C, then by the Bafillus natt after activation in temperature Degree is amplification culture 24h at 36～38 DEG C；
(3) fermentation: Drinking Water is heated up to 50～60 DEG C, 10～15% according to the water yield add soybean protein powder, are sufficiently stirred for being formed greatly Soybean protein powder suspension, then adds dipotassium hydrogen phosphate in soybean protein powder suspension, and regulation pH is 7.0～7.5, goes out at 119～121 DEG C Cool down after bacterium 30min, add the Bafillus natt after step (2) amplification culture, at 36～38 DEG C of bottom fermentation 48h；
(4) fermentation liquid after step (3) being fermented inactivates 35min at 80～85 DEG C, and being then dried under vacuum to solid content at 60～70 DEG C is 30% After, lyophilization, obtain natto powder.
CN201610342975.1A 2016-05-20 2016-05-20 Natto protein powder Pending CN105998726A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610342975.1A CN105998726A (en) 2016-05-20 2016-05-20 Natto protein powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610342975.1A CN105998726A (en) 2016-05-20 2016-05-20 Natto protein powder

Publications (1)

Publication Number Publication Date
CN105998726A true CN105998726A (en) 2016-10-12

Family

ID=57096104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610342975.1A Pending CN105998726A (en) 2016-05-20 2016-05-20 Natto protein powder

Country Status (1)

Country Link
CN (1) CN105998726A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106418548A (en) * 2016-10-17 2017-02-22 张群法 Health-care food formula capable of preventing and treating hypertension, hyperlipidemia and hyperglycemia and production process of health-care food formula
CN106579422A (en) * 2016-11-28 2017-04-26 武汉哈福科技有限公司 Anti-thrombus functional food
CN107125632A (en) * 2017-06-29 2017-09-05 重庆市万源禽蛋食品有限公司 Compound protein powder and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103230478A (en) * 2013-05-02 2013-08-07 广州施健生物科技有限公司 Selenium-rich natto product
CN105054076A (en) * 2015-08-25 2015-11-18 广州施健生物科技有限公司 Alzheimer's disease improving nutritional composition and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103230478A (en) * 2013-05-02 2013-08-07 广州施健生物科技有限公司 Selenium-rich natto product
CN105054076A (en) * 2015-08-25 2015-11-18 广州施健生物科技有限公司 Alzheimer's disease improving nutritional composition and application thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106418548A (en) * 2016-10-17 2017-02-22 张群法 Health-care food formula capable of preventing and treating hypertension, hyperlipidemia and hyperglycemia and production process of health-care food formula
CN106579422A (en) * 2016-11-28 2017-04-26 武汉哈福科技有限公司 Anti-thrombus functional food
CN107125632A (en) * 2017-06-29 2017-09-05 重庆市万源禽蛋食品有限公司 Compound protein powder and preparation method thereof

Similar Documents

Publication Publication Date Title
CN103230478B (en) Selenium-rich natto product
CN102934809B (en) Composition prepared by probiotic-fermented traditional Chinese medicine (TCM) preparation as well as preparation method and application of compound
CN108244432A (en) A kind of fermentation Cordyceps militaris probiotic beverage and preparation method thereof
CN103690627A (en) Electuary having health function of assisting to improve memory
KR101164083B1 (en) Composition comprising glehnia littoralis fr. schmidt et miquel extract for relieving hangover
CN101828598A (en) Health-care food for improving human immunity
CN105998726A (en) Natto protein powder
CN110897147A (en) Dendrobium officinale alcohol-dispelling and liver-protecting composition and preparation method thereof
CN105124605A (en) Health care chewable tablet and preparation method thereof
CN115005437A (en) Enzyme beverage with effects of dispelling effects of alcohol and protecting liver and preparation method thereof
CN105265947B (en) A kind of plant beverage for improving hyperglycaemia and diabetes patient's constitution
CN103598325A (en) Health-care poria cocos yoghourt and preparation method thereof
KR100994196B1 (en) Method for preparing garlic Cheonggukjang fermentation broth
CN105505728A (en) Vinegar drink for dispelling effect of alcohol and protecting liver and preparing method thereof
WO2012092850A1 (en) Anti-alcoholism drug and preparation method therefor
CN103462012B (en) Health-care soft-shelled turtle liquid and preparation method thereof
CN102626164B (en) Liver nourishing tea granules for preventing alcoholic liver disease
CN104719537B (en) A kind of flower tea composition and preparation method thereof
CN102669351B (en) Liver-nourishing tea electuary for preventing alcoholic liver
CN104642607A (en) Low-sugar gingko tea drink and preparation method thereof
CN107372947B (en) Tea bag type blood sugar reducing tea and preparation method thereof
CN105146392A (en) Nutritive milk shake powder and preparation method thereof
Shin et al. Korean Traditional Fermented Soybean Foods and Their Functionalities
KR20100129040A (en) Manufacturing method of health food containing cow sulfur Cheongsimwon raw material using microorganism and health food manufactured by the manufacturing method
CN104757679A (en) Kudzuvine root beverage containing nicotinic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161012